
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC demonstrated robust growth in 2025, with KIMMTRAK generating $400 million in sales, reflecting a 29% year-over-year increase, driven by high penetration rates of over 70% across various geographies and an extended duration of therapy averaging around 14 months. The company is currently focusing on expanding KIMMTRAK's application to cutaneous melanoma, which, if successful, could significantly enhance its commercial prospects, with peak potential annual revenues in this area estimated at $500 million, contingent on positive clinical outcomes. Overall, Immunocore’s strong financial trajectory, driven by solid sales performance and strategic pipeline expansions, supports a positive outlook on the company’s stock.
Bears say
Immunocore Holdings PLC faces a negative outlook due to the potential lack of observed clinical benefits in future PRAME clinical readouts, which is expected to result in a significant downside to current projections. The company may struggle to generate additional successful clinical candidates beyond its current platforms, raising concerns about its ability to diversify its product portfolio. Additionally, treatment-emergent adverse events from ongoing trials imply potential safety concerns, while the consistent treatment landscape indicates a persistent unmet medical need that may limit market potential for its therapies.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares